Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This Item 5.07 disclosure reports the results of Westrock Coffee's 2026 annual meeting of stockholders held on June 5, 2026, including the election of four Class I directors (Mark A. Edmunds, Joe T. Ford, Kenneth M. Parent, and Oluwatoyin Umesiri) and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing directly matches the shareholder_vote_results event type and is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
Omega Healthcare Investors held its 2026 Annual Meeting of Shareholders on June 5, 2026. Shareholders voted on and approved three proposals: election of eight directors, ratification of Ernst & Young LLP as independent auditor, and an advisory vote on executive compensation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Ribbon Communications' annual meeting of stockholders held on June 3, 2026. The filing presents voting results for three proposals: election of nine directors, ratification of Deloitte & Touche LLP as independent auditor, and an advisory vote on named executive officer compensation. All three proposals passed with substantial majorities, representing routine shareholder governance matters that are material to investors' understanding of corporate governance and board composition.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-05
Item 5.02
The Board adopted a revised Director Compensation Policy effective June 4, 2026, modifying the structure of director compensation by splitting RSU awards equally between restricted stock units and a long-term cash award to reduce dilution.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
Shareholders voted at the 2026 Annual Meeting of Stockholders held on June 4, 2026, approving the election of seven directors, the advisory approval of executive compensation, and the ratification of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-05
Item 8.01
Duke Energy Carolinas consummated the issuance and sale of $2.4 billion in mortgage bonds across three series (4.65% due 2031, 5.15% due 2036, and 5.75% due 2056) on June 5, 2026. While this is a material debt financing event affecting the company's capital structure and financial position, it does not fit cleanly into the standard 8-K taxonomy categories. The disclosure is a straightforward debt issuance completion rather than a restatement, impairment, covenant breach, or other more specific event type, warranting classification as "other_material."
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-05
Item 8.01
Humacyte disclosed receipt of a Nasdaq deficiency notice on May 4, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), followed by notification on June 5, 2026, that the company had regained compliance. This disclosure directly addresses delisting risk and continued listing status, which is material to investors assessing the registrant's ability to remain publicly traded.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 8.01
The Company is winding down two material agreements (Native Markets Temporary Use Agreement and Felix Foundation HAUS Agreement) involving approximately $28.7 million in combined asset value as of March 31, 2026. While this involves repositioning of assets rather than a traditional M&A transaction, covenant breach, or other specifically-defined event type, the termination of these material agreements and the return of ~800,000 HYPE tokens represents a significant strategic shift that would affect a reasonable investor's assessment of the Company's operations and asset positioning.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-05
Item 3.02
The filing discloses an unregistered sale of 1,150,000 shares of common stock at $4.82 per share (approximately $5.5 million in gross proceeds) relying on Rule 506 exemption. This is a classic private placement to a sophisticated investor with restricted legend shares, representing a material dilutive issuance that would affect a reasonable investor's assessment of ownership and capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This is a clear disclosure of shareholder vote results from Ladder Capital's June 4, 2026 annual meeting of stockholders. The filing reports voting outcomes for two proposals: (1) re-election of Brian Harris and Mark Alexander as Class III Directors, and (2) ratification of Ernst & Young LLP as independent auditor for 2026. The detailed vote tallies (votes for, votes withheld/against, broker non-votes, and abstentions) are presented in tabular form, which is the standard format for Item 5.07 disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This is a clear disclosure of shareholder voting results from the Annual Meeting held on June 4, 2026, covering three proposals: election of three Class II Directors (Laura Brege, Badreddin Edris, and Jonathan Root), ratification of KPMG LLP as independent auditor, and advisory vote on named executive officer compensation. The filing directly matches Item 5.07 requirements and presents final vote tallies for each proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
Consolidated Water Co. Ltd. held its Annual General Meeting on June 1, 2026, at which shareholders voted on eight proposals including director elections, approval of the 2027 Employee Stock Incentive Plan, authorization of share capital increases, amendments to the Memorandum and Articles of Association, an advisory vote on executive compensation, and ratification of the independent auditor. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-05
Item 8.01
Pinnacle West disclosed an amendment to an at-the-market (ATM) equity distribution agreement permitting the offer and sale of up to $900 million in common stock shares. While the First Amendment itself only modified the forward sale maturity period from 18 to 24 months, the underlying ATM program represents a material dilutive issuance mechanism. The company has already sold approximately $630 million of the authorized shares, with $270 million remaining available, indicating active use of this equity financing facility. This disclosure is material to investors assessing capital structure and shareholder dilution risk.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-05
Item 5.02
The Board approved grants of 7,000,000 restricted shares to four executives and directors (Silverman, Bernstein, Boctor, and Walker) with a two-tranche vesting schedule (50% immediate, 50% at six months). This is a compensatory arrangement for named executives and directors, clearly falling under Item 5.02(e) disclosure of equity grants. The aggregate size and broad distribution to senior leadership makes this material to investors.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-06-05
Item 1.01
Howard Hughes Insurance Holdings, LLC (a subsidiary of Howard Hughes Holdings Inc.) completed the acquisition of all outstanding shares of Vantage Group Holdings, Ltd. for $2.1 billion in cash on June 4, 2026. This material acquisition represents a significant capital deployment and business combination affecting the registrant's strategic position and financial condition.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-05
Item 3.02
Howard Hughes Holdings Inc. completed an unregistered sale of preferred stock under Section 4(a)(2) and Regulation D exemptions. The securities have not been and will not be registered under the U.S. Securities Act of 1933, representing a material private placement capital-raising event.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-05
Item 3.03
The filing discloses a material modification to the rights of security holders, specifically relating to preferred stock rights, in connection with the transactions described in the 8-K.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This Item 5.07 disclosure reports the results of PTC Therapeutics' Annual Meeting held June 2, 2026, including election of four Class I directors, ratification of Ernst & Young LLP as independent auditor, and approval of a non-binding advisory vote on named executive officer compensation. The filing presents vote tallies for each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 3.03
GPGI completed a reincorporation from Delaware to Nevada on June 5, 2026, materially modifying stockholder rights by changing the governing law and corporate charter. The reincorporation represents a significant corporate governance restructuring that affects the legal framework governing shareholder rights.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-05
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from nLIGHT's 2026 annual meeting held on June 5, 2026. The filing reports voting outcomes on three proposals: election of a Class II director (Geoffrey Moore), ratification of KPMG LLP as independent auditor, and an advisory vote on named executive officer compensation. The compensation proposal notably failed, with 24.6 million votes against versus 15.8 million for—a material governance signal that would affect investor assessment of management alignment.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-05
Item 1.01
Planet Labs entered into an Equity Distribution Agreement authorizing the sale of up to $1.5 billion of Class A common stock through an "at the market offering" program with multiple sales agents and forward purchasers. This is a material dilutive equity issuance that will increase share count and is a significant capital-raising activity for the company, disclosed under Item 1.01 as a material definitive agreement.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This Item 5.07 filing discloses the results of Navient Corporation's 2026 Annual Meeting of Shareholders held on June 4, 2026, including voting outcomes on four proposals: election of six directors, ratification of KPMG LLP as independent auditor, advisory approval of executive compensation, and say-on-pay frequency. The detailed vote tallies (For/Against/Abstain/Broker Non-Votes) for each proposal are the core disclosure, making this a textbook shareholder_vote_results event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-05
Item 3.02
This is a classic private placement of unregistered equity securities. Cenntro issued 1,000,000 shares of common stock at $3.93 per share for approximately $3.93 million in gross proceeds, relying on Section 4(a)(2) and Regulation S exemptions from Securities Act registration. The filing explicitly discloses the unregistered sale under Item 3.02, and the transaction closed on June 2, 2026. This is material as it represents significant dilution to existing shareholders and a material capital raise.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 3.03
The company effected a 1-for-20 reverse stock split on June 5, 2026, which was authorized by stockholders on April 29, 2026. This capital restructuring consolidates shares and adjusts exercise prices and share reserves, materially modifying the rights and economic interests of all security holders.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-06-05
Item 5.02
Carrie D'Andrea, Vice President of Clinical Operations, is ceasing employment effective June 5, 2026. While the disclosure also mentions severance benefits and a consulting agreement, the principal disclosed action is the departure of a named officer. The filing centers on her separation from the Company, making exec_departure the most salient classification, though the compensation elements (severance and consulting fee) are secondary to the departure itself.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This Item 5.07 filing discloses the results of Prairie Operating Co.'s 2026 Annual Meeting of Stockholders held on June 3, 2026, including voting outcomes for two proposals: election of four directors (Richard N. Frommer, Jonathan Gray, Stephen Lee, and Erik Thoresen) and ratification of Deloitte & Touche LLP as the independent auditor. The detailed vote tallies (votes for, against, abstentions, and broker non-votes) are the core disclosure required by Item 5.07, making this a clear shareholder vote results event that is material to investors assessing board composition and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-05
Item 5.07
Stockholders approved a reverse stock split proposal at a Special Meeting held on June 1, 2026, with the Board authorized to implement a 1-for-2 to 1-for-25 reverse stock split ratio at its discretion. The Board subsequently approved and announced implementation of a 1-for-6 reverse stock split, effective June 12, 2026.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 8.01
Edesa Biotech disclosed favorable exploratory clinical data for paridiprubart showing a 32% relative reduction in 28-day mortality in AKI patients and a 23% relative reduction in MAKE30 incidence, presented at the ERA Congress. While this represents material clinical progress for a biotech company's lead candidate, the disclosure emphasizes these are exploratory, post-hoc analyses not prespecified in the statistical plan, with nominal p-values not adjusted for multiplicity and explicit caution that confirmatory studies would be required. This clinical milestone does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, restatement, or litigation), making it best classified as other_material given its potential significance to investors assessing the company's pipeline prospects.
View raw filing on EDGAR →
8-K
Covenant Breach
confidence 92%
filed 2026-06-05
Item 1.01
The Company disclosed anticipated defaults under its Credit Agreement, specifically failures to satisfy financial covenants (minimum liquidity and Collateral Coverage Ratio) and reporting obligations. The lenders granted a forbearance agreement through June 12, 2026, explicitly reserving all rights and remedies.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-05
Item 5.02
The Board approved an Employee Retention Program providing cash-based retention awards and nonqualified stock option grants to named executive officers, including CEO Douglas W. Campbell ($1.2M cash plus 190,600 options), CFO Jonathan Collins ($563K cash plus 45,380 options), COO Jamie Fischer ($531K cash plus 50,660 options), and Chief Accounting Officer Vickie D. Judy ($300K cash plus 16,336 options).
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-05
Item 8.01
A Special Committee is conducting an ongoing strategic review evaluating financing, recapitalization, restructuring, M&A, and other strategic transactions, with engagement of major financial advisors (Houlihan Lokey and FTI Consulting) and active discussions with lenders regarding potential credit agreement amendments.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-05
Item 1.01
AmperCap Acquisition Company consummated its IPO on June 4, 2026, raising $125 million through the sale of 12.5 million units and entering into multiple material definitive agreements (underwriting, business combination marketing, private placement, and trust agreements) in connection with the offering.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-05
Item 3.02
AmperCap completed a private placement of 512,500 units at $10.00 per unit to the Sponsor, EBC, and third-party investors simultaneously with the IPO closing, issued pursuant to Section 4(a)(2) exemption from registration.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-05
Item 5.02
Three individuals—John Salemi, Luis Pena Kegel, and Alfredo Flores Ibarrola—were appointed to the board of directors effective June 2, 2026, in connection with the IPO, with each also appointed to the Audit Committee and Compensation Committee, and Salemi chairing both committees.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-05
The filing discloses a material disposition of assets: VSee Health sold all equity securities of its wholly-owned subsidiary VSee Lab to Milton Chen (the co-CEO and Chairman) in exchange for Chen's transfer of 2,870,069 shares of common stock to the Company. This is a significant restructuring involving a change of control of a subsidiary and a material equity transaction, disclosed under Items 1.01 (Entry into Material Definitive Agreement), 2.01 (Completion of Acquisition or Disposition of Assets), and 3.02 (Unregistered Sales of Equity Securities). While an executive departure also occurs (Chen's resignation as co-CEO and Chairman), the central disclosed event is the asset disposition and equity swap transaction.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-06-05
Item 5.02
David Bailey, a co-founder and board member of RTB Digital, is departing the board of directors effective June 1, 2026, to focus on his CEO role at Nakamoto, Inc. The filing explicitly states his departure and notes he was a "founding investor and board member" who participated in recent funding rounds. While the departure is amicable and not due to disagreement, the loss of a founding board member who was actively involved in capital raises is material to investors' assessment of the company's governance and continuity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-05
Item 3.02
This Item 3.02 disclosure reports an unregistered sale of 1,318,837.5608 common shares for $33.3 million in aggregate consideration, exempt under Section 4(a)(2) and Regulation D Rule 506. The sale includes multiple share classes (F-I, F-S, and E) sold to third-party investors and insiders. This is a classic dilutive equity issuance in a continuous private offering, material to investors assessing ownership dilution and capital raising activity.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
Seadrill held its Annual General Meeting on June 3, 2026, at which shareholders voted on and approved six proposals: board size determination, re-election of nine directors, appointment of PwC US as auditor, director remuneration approval, advisory vote on named executive officer compensation, and Amendment No. 1 to the 2022 Management Incentive Plan.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This Item 5.07 filing discloses the final results of three shareholder votes at Zumiez's Annual Meeting: election of three directors (Thomas D. Campion, Liliana Gil Valletta, Carmen R. Bauza), an advisory vote on executive compensation, and ratification of Baker Tilly US, LLP as independent auditor. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-05
Item 1.01
Seres Therapeutics amended its Asset Purchase Agreement with Société des Produits Nestlé S.A., materially restructuring contingent milestone payment obligations by terminating $125M and $150M future milestone payments in exchange for a $25M immediate payment. The company also amended its lease agreement, reducing square footage by approximately 55% and decreasing lease payments by $33.9M.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-05
Item 2.02
ABM Industries disclosed financial results for the quarter ended April 30, 2026, through a press release filed under Item 2.02.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 8.01
This disclosure announces translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, an anti-APRIL monoclonal antibody candidate. The announcement includes positive preliminary safety findings (no serious adverse events, dose-limiting toxicities, or discontinuations in 49 healthy volunteers up to 320 mg) and supportive pharmacokinetic/pharmacodynamic modeling suggesting potential for less-frequent dosing. While this is a clinical development milestone for a pipeline asset, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation). The disclosure would be material to investors evaluating the company's pipeline progress and risk profile, particularly given the positive safety profile and advancement toward Phase 2 dosing in IgAN patients expected in Q3 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
FTI Consulting held its 2026 Annual Meeting of Shareholders on June 3, 2026, with voting results on three proposals: election of eight directors, ratification of KPMG LLP as independent auditor, and an advisory vote on named executive officer compensation.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-05
Item 8.01
The Board authorized an additional $370.0 million share repurchase authorization on June 3, 2026, bringing the aggregate authorization to $2.6 billion, signaling management's confidence in the stock's valuation and the company's financial position.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
MBX Biosciences held its 2026 Annual Meeting on June 4, 2026, at which stockholders approved the election of two Class II directors (Patrick J. Heron and Edward T. Mathers) for three-year terms and ratified Ernst & Young LLP as the company's independent auditor.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-05
Item 7.01
The company announced a registered direct offering of 7,500,000 common shares for $15 million in aggregate gross proceeds. This is a material equity issuance that dilutes existing shareholders and signals capital-raising activity, characteristic of a dilutive_issuance event. The pricing and share count are explicitly disclosed, indicating a completed or priced offering.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from PMV Pharmaceuticals' June 4, 2026 Annual Meeting. The filing reports voting outcomes on three proposals: election of Class III directors (David H. Mack and Laurie Stelzer), non-binding advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The detailed vote tallies (FOR, AGAINST, WITHHELD, ABSTAIN, BROKER NON-VOTE) are the hallmark of shareholder meeting result disclosures and are material to investors assessing governance and board composition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-05
Item 5.07
This is a clear disclosure of shareholder vote results from the June 4, 2026 annual meeting, covering three proposals: election of Class I directors (Joshua E. Schechter and Jill H. Bright), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. The filing explicitly states voting tallies for each proposal, which is the hallmark of Item 5.07 shareholder_vote_results disclosures.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-05
Item 5.01
The Company entered into a Transaction Support Agreement with debtholders that establishes a conditional equity conversion mechanism whereby noteholders may convert $98.5 million in 2027 PIK Notes into 80–95% of the Company's fully diluted equity upon an Event of Default or after December 31, 2027, representing a potential material change of control.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-05
Item 8.01
Dominion Energy entered into an underwriting agreement on June 3, 2026 for the sale of $825 million in senior notes due 2036. While this is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, it does not fit cleanly into the more specific event categories (it is not a dilutive equity issuance, M&A activity, or a financial covenant breach). The disclosure is material as it represents a significant financing transaction, but the taxonomy lacks a dedicated "debt issuance" category.
View raw filing on EDGAR →